Nevertheless, given the observed effects on immune checkpoint regulation and the potential of this approach to inhibit several oncogenic pathways simultaneously, p53-based immunotherapy may hold significant therapeutic potential for the treatment of hematologic malignancies. The gene discussed is TP53; the disease is hematologic disorder.